CytomX Therapeutics, Inc. CTMX
2.13 USD +0.15 (+7.58%)
At closeNov 11, 2026, 6:00 PM EST
2.16 +0.03 +1.41%
After hours · Nov 11, 6:00 PM ET
1.97 Day range 2.17
1.90 52-week range 8.21
- YTD
- -50.00%
- 1 year
- -48.05%
News
seekingalpha.com CytomX Therapeutics, Inc. (CTMX) Q3 2026 Earnings Call Transcript CytomX Therapeutics, Inc. ( CTMX ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Chris Ogden - SVP, CFO & Secretary Sean McCarthy - Chairman & CEO Conference Call…
benzinga.com Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $12 Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and raises the price target from $11 to $12.
marketbeat.com CytomX Therapeutics Q3 Earnings Call Highlights CytomX Therapeutics NASDAQ: CTMX plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in…
zacks.com CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago.
benzinga.com CytomX Therapeutics Q3 2026 Earnings Call Transcript CytomX Therapeutics (NASDAQ:CTMX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
globenewswire.com CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update - Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC)…
benzinga.com CytomX Therapeutics Q3 EPS $(0.09) Beats $(0.10) Estimate, Sales $1.688M Miss $4.925M Estimate CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 0 percent. This is unchanged from the same period last year.…
seekingalpha.com CytomX Therapeutics: Trading Near Cash Value While Varseta-M Heads Toward Pivotal Trials CytomX Therapeutics is rated Buy, driven by positive clinical data for Varseta-M and a robust $367M cash runway after significant dilution. Varseta-M, targeting late-line colorectal cancer, achieved…
globenewswire.com CytomX Therapeutics to Present at Upcoming November Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that…
globenewswire.com CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it…
defenseworld.net CytomX Therapeutics (NASDAQ:CTMX) Reaches New 1-Year Low – Should You Sell? CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) shares reached a new 52-week low on Wednesday. The company traded as low as $2.32 and last traded at $2.33, with a volume of 5,223,013…
seekingalpha.com CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com CytomX Therapeutics to Present at Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that…
globenewswire.com CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H…
defenseworld.net AWM Investment Company Inc. Acquires Shares of 150,000 CytomX Therapeutics, Inc. $CTMX AWM Investment Company Inc. acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ: CTMX) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor…
benzinga.com JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11 JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
defenseworld.net Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX Bank of America Corp DE boosted its position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 1,064.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange…
seekingalpha.com CytomX Therapeutics: Promising Varseta-M With Comfortable Runway CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limiting drug activity in healthy tissue. Their lead asset is Varseta-M, which has interesting early…- benzinga.com Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14 Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.
seekingalpha.com CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
marketbeat.com CytomX Therapeutics Q2 Earnings Call Highlights CytomX Therapeutics NASDAQ: CTMX said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while…
zacks.com CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to break-even earnings per share a year ago.
benzinga.com CytomX Therapeutics Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $1.418M Miss $12.308M Estimate CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. The company reported quarterly sales of $1.418…
globenewswire.com CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - -…
globenewswire.com CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the…
globenewswire.com CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it…
benzinga.com CytomX Expands Collaboration And Licensing Agreement With Regeneron To Create Conditionally-Activated Bispecific Cancer Therapies Utilizing CytomX's Probody Therapeutic Platform And Regeneron's Veloci-Bi Bispecific Antibody Development Platform - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms -- CytomX to receive $37…- benzinga.com HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $17 to $11.
- benzinga.com CytomX Therapeutics Q1 EPS $(0.10) Beats $(0.20) Estimate, Sales $10.258M Beat $4.713M Estimate CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.20) by 50 percent. This is a 137.04 percent decrease over earnings of…
benzinga.com Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12 Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $10 to $12.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16 Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $10 to $16.
- benzinga.com Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16 Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $8 to $16.
benzinga.com Why Is CytomX Therapeutics Stock Falling On Wednesday? CytomX stock falls after $250 million share sale, even as new colorectal cancer data shows strong response and growth potential.
benzinga.com Guggenheim Maintains Buy on CytomX Therapeutics, Raises Price Target to $15 Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $10 to $15.- benzinga.com Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $11 Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and raises the price target from $6 to $11.
benzinga.com CytomX Therapeutics Files Prospectus For Potential Offerings Of Stock, Debt, Warrants And Units Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identified above from time to time in one or more offerings. This prospectus provides you with a general…- benzinga.com CytomX Therapeutics Announces Public Offering Of $250M In Stock And Pre-Funded Warrants In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock at the public offering price, less underwriting discounts…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally CytomX Therapeutics stock jumps in premarket trading after Phase 1 data for Varseta-M showed tumor responses in colorectal cancer patients.- benzinga.com HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Raises Price Target to $17 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $10 to $17.
benzinga.com Crude Oil Down 4%; Dollar Tree Earnings Top Views - benzinga.com JP Morgan Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $12 JP Morgan analyst Anupam Rama upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweight and raises the price target from $7 to $12.
benzinga.com Nebius Group, CytomX Therapeutics, National Storage Affiliates Trust And Other Big Stocks Moving Higher On Monday Dow Jones index up 500 points; Nebius Group NV shares rise 12.7% on AI agreement with Meta Platforms; several other stocks record gains.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Market-Moving News for March 16th NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated Capacity Across Multiple Locations Using NVIDIA Vera Rubin Platform Starting Early 2027 CTMX: 70%
benzinga.com Earnings Scheduled For March 16, 2026 - benzinga.com CytomX Therapeutics Announces Phase 1 Expansion Data For EpCAM PROBODY ADC, Varseta-M In Late-Line Metastatic CRC; Preliminary Data Are As Of January 16 Data Cutoff From Ongoing CTMX-2051-101 Phase 1 Study - Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W -- Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg --…
- benzinga.com CytomX Therapeutics Q4 EPS $(0.22) Misses $(0.09) Estimate, Sales $663.000K Miss $7.900M Estimate CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.09) by 136.56 percent. This is a 195.65 percent decrease over…
benzinga.com CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss of 9 cents per share. Stock fell 3.9% on Friday.